Healthcare Industry News: Cephalon
News Release - May 9, 2007
Tulip BioMed Appoints New President and Chief Operating Officer; Chief Financial Officer Adds Secretary and Treasurer Titles
SAN DIEGO, CA--(Healthcare Sales & Marketing Network)--May 9, 2007 -- Tulip BioMed(TM), Inc. (Other OTC:TPBD.PK ), a developer of medical devices and patented technologies for the living tissue markets, including plastic, cosmetic, and orthopedic surgeries, today announced that it has appointed Richard P. Burgoon, Jr. as its president and chief operating officer and Kenneth J. Yonika, chief financial officer, as its secretary and treasurer.Mr. Burgoon has spent over 20 years of his professional career within the life science industry. Most recently he served as chief executive officer to Aeolus Pharmaceuticals, Inc. where, as sole employee of Aeolus, he was responsible for managing outside consultants and overseeing: $7.5 million in new financing; reducing expenditures by 41% (2004 vs. 2005) and 21% (2005 vs. 2006); advancing clinical development of one compound; and establishing three additional compounds for development.
Burgoon is a co-founder of Allon Therapeutics, Inc., a publicly traded CNS-focused company headquartered in Vancouver, British Columbia; GenSpera, Inc., a privately held oncology-focused company headquartered in Santa Monica, California; and ChemNavigator, a privately held chemical-informatics, drug-discovery company headquartered in San Diego. Burgoon previously held positions as senior vice president operations and general counsel to Arena Pharmaceuticals, Inc.; director business development - USA to Choongwae Pharma Corporation, South Korea's largest publicly traded pharmaceutical company; senior director to Cephalon, Inc.; intellectual property counsel to IDEC Pharmaceuticals (now, Biogen-IDEC); staff attorney to Beckman Instruments, Inc. (now Beckman Coulter Inc.); and as a partner with Xmark Funds, LLC, a specialty purpose investment fund based in Stamford, Connecticut.
As a member of the California Bar Association, Mr. Burgoon began his career as an associate with the national law firm of Lyon & Lyon. Burgoon earned his MBA from San Diego State University, his J.D. from the Franklin Pierce Law Center and undergraduate degrees in biology, psychology and political science from the University of California, Irvine.
The company also announced Mr. Yonika's appointment to the role of secretary and treasurer, in addition to serving as chief financial officer. Mr. Yonika has served the company as a consultant since August 2006. Yonika, a licensed certified public accountant (CPA) and senior finance executive with more than 18 years experience working with publicly traded companies, has held management responsibility for financial reporting with a billion dollar biotechnology company as well as several other biotechnology and high technology start-ups. In addition to financial and external reporting, his broad-based experience includes initial public offerings, mergers and acquisitions, international business as well as managing operational issues surrounding both logistics and manufacturing.
Prior to joining Tulip BioMed, Yonika worked with DrugMax, Inc., a publicly traded Connecticut-based national specialty pharmacy and drug distributor, where he served on the senior management team. Prior to his role with DrugMax, Mr. Yonika worked with Carlsbad-based Invitrogen as well as several other public companies in financial and external reporting roles. Mr. Yonika is a former big four CPA with ties to national accounting and law firms as well as several investment banks based in Southern California. The company anticipates that Mr. Yonika will lead Tulip BioMed, currently a non-reporting publicly traded company, to meet all requirements of the SEC and Sarbanes-Oxley.
Tulip BioMed's chairman and CEO, John Johnson, commented on the company's recent appointments. "I am excited about the changes of the past few months. With the overhaul of our board of directors, Tulip now has the ability to attract individuals like Rick and Ken to our team. Both are exceptional businessmen, and I look forward to working with them to grow the company and enhance shareholder value. Our introductory proprietary products have been very well received by physicians worldwide. We believe the positive changes in the company's management and board can help capitalize on the industry's interest in our timely product line."
Doctors and industry professionals who would like to discuss the advantages of Tulip BioMed's products are encouraged to call the company at 800-978-8547.
About Tulip BioMed, Inc.
Tulip BioMed, Inc. (Other OTC:TPBD.PK ), a Nevada corporation, has its operations based in San Diego, California. Founded in 2004, Tulip BioMed, Inc. is a medical devices company that manufactures and distributes patented technologies for the living tissue markets, including plastic and cosmetic surgery, biopsy, orthopedic surgery, and stem cell therapy. Tulip BioMed, Inc. is the exclusive licensee of patented syringe connection devices that use the worldwide recognized "Tulip" brand name. Tulip BioMed, Inc. manufactures, markets, and distributes medical devices, adapted with these and other patented technologies, to physicians, clinics, military, health organizations, hospitals and other distribution outlets. For more information please visit our website at: www.tulipbiomed.com. Products are available for sale at www.tulipdisposable.com.
Safe Harbor: This press release contains certain forward-looking information about Tulip BioMed, Inc., which is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of Tulip BioMed, Inc., that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include: our lack of operating revenue and earnings history, our need for additional capital to pursue our business strategy. We are a non-reporting company and as such do not make periodic filings with the Securities and Exchange Commission. We trade on the Pink Sheets and there can be no assurances that a liquid market will develop in our securities. Readers are cautioned not to place undue reliance on these forward-looking statements. Tulip BioMed, Inc. does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Source: Tulip BioMed
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
